Antianginal Medications

Introduction to Antianginal Medications

Antianginal medications are used to manage chronic stable angina, with the American College of Cardiology recommending beta-blockers as first-line therapy, and ranolazine as an add-on therapy when symptoms persist despite standard treatment 1, 2

Ranolazine works through a different mechanism, likely membrane ion-channel effects, and does not significantly reduce heart rate or affect blood pressure, according to the American College of Cardiology 3
Calcium channel blockers (e.g., amlodipine, verapamil, or diltiazem) are effective alternatives for stable angina management, as recommended by the American College of Cardiology 4

Ranolazine can be particularly useful in patients with bradycardia and/or hypotension due to its neutral hemodynamic profile, and may be effective in patients with left ventricular hypertrophy, diabetes mellitus (reducing HbA1c levels), and microvascular angina (though evidence is mixed) 1
Ranolazine may be considered in patients with left ventricular systolic dysfunction (LVEF <40%), providing an alternative when beta-blockers or calcium channel blockers are contraindicated or poorly tolerated, as suggested by the European Society of Cardiology 2
Ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis, and in patients taking strong CYP3A inhibitors or inducers 1, 5

Ranolazine should be used with caution in patients taking digoxin (increases digoxin concentration), moderate CYP3A inhibitors, P-glycoprotein inhibitors, simvastatin, or metformin 1, 5
The combination of ranolazine and dofetilide presents serious cardiac risks due to QT interval prolongation, and should be avoided if possible, as recommended by the European Society of Cardiology 1
Pre-existing QT prolongation or congenital long QT syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia, heart failure, female gender, advanced age, and hepatic or renal impairment are factors that increase the risk of cardiac arrhythmias when using ranolazine and dofetilide 1

Baseline assessment includes ECG to evaluate QTc interval, renal function, hepatic function, and medication review for potential interactions, as suggested by the European Society of Cardiology 6
Follow-up monitoring includes ECG after dose adjustments, symptom assessment for side effect management, and periodic renal function tests in at-risk patients, as recommended by the American College of Cardiology 6

The recommended starting dose of ranolazine is 500 mg twice daily, which can be increased to 1000 mg twice daily based on clinical response, as recommended by the European Society of Cardiology and the American College of Cardiology 6, 5, 4, 7

Ranolazine's major side effects include constipation, nausea, dizziness, headache, and QTc interval prolongation, which can be managed through dose adjustment, symptomatic treatment, and monitoring, as recommended by the American Heart Association 6
Constipation occurs commonly with ranolazine therapy, and management includes increasing fluid intake, dietary fiber, and considering mild laxatives if persistent, as suggested by the European Society of Cardiology 6
The American College of Cardiology suggests setting realistic expectations for symptom improvement, as ranolazine provides modest but significant improvements in exercise duration and reduction in angina frequency 5